Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Infinity Pharmaceuticals, Inc. Clear all
Not listed Phase 2 Interventional

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

NCT03961698
View directory record Official record
Conditions
Breast Cancer, Renal Cell Carcinoma
Interventions
IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel, Bevacizumab
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
24
States / cities
Chandler, Arizona • Tucson, Arizona • Fullerton, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 3, 2026, 6:55 PM EDT
Terminated Phase 2 Interventional

A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma

NCT00627419
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
IPI-504
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
17
States / cities
Tuscon, Arizona • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 2 Interventional

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

NCT01362400
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
IPI 504 plus Docetaxel, Placebo plus Docetaxel
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
41
States / cities
Chandler, Arizona • Tucson, Arizona • Orange, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study With IPI-926 in Patients With Myelofibrosis

NCT01371617
View directory record Official record
Conditions
Primary Myelofibrosis, Fibrosis, Bone Marrow
Interventions
IPI-926
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Palo Alto, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

NCT01427946
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
IPI-504, Everolimus
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Aurora, Colorado • Tampa, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

NCT03719326
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Ovarian Cancer
Interventions
Etrumadenant, IPI-549, Pegylated liposomal doxorubicin (PLD), nanoparticle albumin-bound paclitaxel (NP)
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
20
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 3, 2026, 6:55 PM EDT
Terminated Phase 1 Interventional

Dose Escalation of IPI-493 in Hematologic Malignancies

NCT01193491
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
IPI-493
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

NCT01871675
View directory record Official record
Conditions
Lymphoma, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, T-cell Lymphoma
Interventions
IPI-145, Rituximab, Bendamustine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer

NCT00564928
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms, Cancer of the Prostate
Interventions
IPI-504
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
10
States / cities
San Bernardino, California • Stanford, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 3, 2026, 6:55 PM EDT
Not listed Phase 1 Interventional

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

NCT02637531
View directory record Official record
Conditions
Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G), High-circulating Myeloid-derived Suppressor Cells (Part H)
Interventions
IPI-549 (eganelisib), Nivolumab
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
11
States / cities
San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors

NCT00606814
View directory record Official record
Conditions
Solid Tumors
Interventions
IPI-504, docetaxel
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Not applicable Interventional

IPI-926 Extension Protocol for Continuation of Treatment With IPI-926

NCT01609179
View directory record Official record
Conditions
Basal Cell Carcinoma, Chondrosarcoma
Interventions
IPI-926
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Aurora, Colorado • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma

NCT00113204
View directory record Official record
Conditions
Multiple Myeloma
Interventions
IPI-504
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 20, 2008 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

NCT03980041
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Solid Tumor, Advanced Cancer
Interventions
IPI-549 (eganelisib), Nivolumab, Placebos
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Fort Wayne, Indiana • Baltimore, Maryland • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 3, 2026, 6:55 PM EDT
Terminated Phase 1 Interventional

A Phase 1 Dose Escalation Study of IPI-493

NCT00724425
View directory record Official record
Conditions
Advanced Malignancies
Interventions
IPI-493
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Scottsdale, Arizona • Encinitas, California • Santa Monica, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 1Phase 2 Interventional

A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer

NCT01130142
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
IPI-926 plus gemcitabine, Placebo plus gemcitabine
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Tucson, Arizona • San Diego, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 3, 2026, 6:55 PM EDT
Withdrawn Phase 2 Interventional

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

NCT00969917
View directory record Official record
Conditions
Dedifferentiated Liposarcoma
Interventions
IPI-504
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 3, 2026, 6:55 PM EDT
Terminated Phase 2 Interventional Results available

IPI-504 in NSCLC Patients With ALK Translocations

NCT01228435
View directory record Official record
Conditions
Lung Cancer, Stage IIIb Lung Cancer, Stage IV Lung Cancer
Interventions
IPI-504
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 3, 2026, 6:55 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

NCT00817362
View directory record Official record
Conditions
Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Cancer of the Breast
Interventions
IPI-504, Trastuzumab
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Palm Springs, California • Boca Raton, Florida • Davie, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

NCT00761696
View directory record Official record
Conditions
Neoplasms
Interventions
IPI-926
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Scottsdale, Arizona • Redwood City, California • Aurora, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

NCT00431015
View directory record Official record
Conditions
Lung Cancer
Interventions
IPI-504
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
11
States / cities
Los Angeles, California • New Haven, Connecticut • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

NCT01383538
View directory record Official record
Conditions
Pancreatic Cancer, Adenocarcinoma, Pancreatic Neoplasms
Interventions
FOLFIRINOX, IPI-926
Drug
Lead sponsor
Andrew Ko
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 3, 2026, 6:55 PM EDT
Withdrawn Phase 1 Interventional

A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

NCT02640833
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma
Interventions
Duvelisib, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Tucson, Arizona • Chicago, Illinois • Harvey, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 3, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

NCT00276302
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
Interventions
IPI-504
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Oct 3, 2026, 6:55 PM EDT